BioCryst Pharmaceuticals Inc (BCRX) stock
BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.50+0.05 (+0.67%)
Close on Nov 17, 2026Market cap $1.92BP/E –Yield –
BioCryst Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
BioCryst Pharmaceuticals's price to sales ratio was 2.1× on Nov 11, 2026, against 2.5× a year earlier. Over the last 5 years it ranged from 2.1× to 24.4×, with a median of 4.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.1× | −0.7 |
| 2025 | Dec 31, 2025 | 2.7× | −1.0 |
| 2024 | Dec 31, 2024 | 3.8× | +0.2 |
| 2023 | Dec 29, 2023 | 3.6× | −5.4 |
| 2022 | Dec 30, 2022 | 9.0× | −12.9 |
| 2021 | Dec 31, 2021 | 21.8× | −2.7 |
| 2020 | Dec 31, 2020 | 24.6× | −7.6 |
| 2019 | Dec 31, 2019 | 32.2× | −8.4 |
| 2018 | Dec 31, 2018 | 40.6× | +24.6 |
| 2017 | Dec 29, 2017 | 16.0× | −5.3 |
| 2016 | Dec 30, 2016 | 21.2× | +5.8 |
| 2015 | Dec 31, 2015 | 15.4× | −31.2 |
| 2014 | Dec 31, 2014 | 46.7× | +5.3 |
| 2013 | Dec 31, 2013 | 41.3× | +38.7 |
| 2012 | Dec 31, 2012 | 2.6× | +2.6 |
| 2011 | Dec 30, 2011 | 0.0× | – |
See a number that looks wrong?